{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:59:05Z","timestamp":1790873945758,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer and presents histologically with a unique pattern of discohesive growth. An expert consensus panel was convened at the annual meeting of the American Society of Breast Surgeons to discuss disease specific management considerations and best practice when caring for women with ILC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>At the annual meeting of the American Society of Breast Surgeons held in Las Vegas, Nevada from April 30 to May 4, 2025, a panel convened to specifically address the intricacies of managing ILC. Panelists completed an independent literature review for each identified subtopic that was summarized and reviewed by panel moderators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The multidisciplinary management of ILC is nuanced and special considerations are essential to optimize treatment. Magnetic resonance imaging of the breast can improve the accuracy of preoperative staging. Surgeons should account for the limitations of imaging with respect to margin resection in lumpectomy. When considering the application of trials guiding omission of ALND in surgery for ILC, surgeons can rely on several studies that have included subanalyses of patients with ILC confirming safety in appropriately selected patients. Use of neoadjuvant therapy should be based on molecular subtype rather than tumor histology. Genetic testing for patients with ILC should include analysis of\n                      <jats:italic>CDH1<\/jats:italic>\n                      mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Awareness and consideration of nuances around the management of ILC, including those discussed in the present study, can help clinicians provide optimal, evidenced based care to women presenting with ILC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20368-y","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:09:05Z","timestamp":1786968545000},"page":"9933-9943","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multidisciplinary Management Considerations in Invasive Lobular Breast Cancer: It Isn\u2019t Just Ductal"],"prefix":"10.1245","volume":"33","author":[{"given":"Anna C.","family":"Beck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn F.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan R.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian M.","family":"Erdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"20","key":"20368_CR1","doi-asserted-by":"publisher","first-page":"e70061","DOI":"10.1002\/cncr.70061","volume":"131","author":"AN Giaquinto","year":"2025","unstructured":"Giaquinto AN, et al. Lobular breast cancer statistics, 2025. Cancer. 2025;131(20):e70061.","journal-title":"Cancer."},{"key":"20368_CR2","unstructured":"Bassett LW, Bassett LW. Diagnosis of diseases of the breast. 2nd ed. Elsevier\/Saunders; 2005. 645 pp."},{"key":"20368_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/BD-2009-0277","volume":"30","author":"KJ Dedes","year":"2008","unstructured":"Dedes KJ, Fink D. Clinical presentation and surgical management of invasive lobular carcinoma of the breast. Breast Dis. 2008;30:31\u20137.","journal-title":"Breast Dis."},{"issue":"1","key":"20368_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiology.178.1.1984294","volume":"178","author":"DJ Hilleren","year":"1991","unstructured":"Hilleren DJ, et al. Invasive lobular carcinoma: mammographic findings in a 10-year experience. Radiology. 1991;178(1):149\u201354.","journal-title":"Radiology."},{"issue":"5","key":"20368_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2214\/ajr.161.5.8273634","volume":"161","author":"KN Krecke","year":"1993","unstructured":"Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol. 1993;161(5):957\u201360.","journal-title":"AJR Am J Roentgenol."},{"issue":"3","key":"20368_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1148\/radiology.185.3.1438749","volume":"185","author":"M Le Gal","year":"1992","unstructured":"Le Gal M, et al. Mammographic features of 455 invasive lobular carcinomas. Radiology. 1992;185(3):705\u20138.","journal-title":"Radiology."},{"issue":"2","key":"20368_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2214\/ajr.172.2.9930776","volume":"172","author":"RS Butler","year":"1999","unstructured":"Butler RS, et al. Sonographic evaluation of infiltrating lobular carcinoma. AJR Am J Roentgenol. 1999;172(2):325\u201330.","journal-title":"AJR Am J Roentgenol."},{"key":"20368_CR8","doi-asserted-by":"crossref","unstructured":"Helvie MA, et al. Invasive lobular carcinoma. Imaging features and clinical detection. Invest Radiol. 1993;28(3):202-7.","DOI":"10.1097\/00004424-199303000-00002"},{"issue":"1","key":"20368_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1148\/radiology.195.1.7892476","volume":"195","author":"CP Paramagul","year":"1995","unstructured":"Paramagul CP, Helvie MA, Adler DD. Invasive lobular carcinoma: sonographic appearance and role of sonography in improving diagnostic sensitivity. Radiology. 1995;195(1):231\u20134.","journal-title":"Radiology."},{"issue":"3","key":"20368_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1148\/radiol.2333031484","volume":"233","author":"WA Berg","year":"2004","unstructured":"Berg WA, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830\u201349.","journal-title":"Radiology."},{"issue":"1","key":"20368_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1148\/rg.291085100","volume":"29","author":"JK Lopez","year":"2009","unstructured":"Lopez JK, Bassett LW. Invasive lobular carcinoma of the breast: spectrum of mammographic, US, and MR imaging findings. Radiographics. 2009;29(1):165\u201376.","journal-title":"Radiographics."},{"issue":"1","key":"20368_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1148\/radiol.2251011029","volume":"225","author":"WP Evans","year":"2002","unstructured":"Evans WP, et al. Invasive lobular carcinoma of the breast: mammographic characteristics and computer-aided detection. Radiology. 2002;225(1):182\u20139.","journal-title":"Radiology."},{"issue":"3","key":"20368_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1148\/radiology.184.3.1324506","volume":"184","author":"GM Newstead","year":"1992","unstructured":"Newstead GM, Baute PB, Toth HK. Invasive lobular and ductal carcinoma: mammographic findings and stage at diagnosis. Radiology. 1992;184(3):623\u20137.","journal-title":"Radiology."},{"issue":"24","key":"20368_CR14","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1001\/jama.2014.6095","volume":"311","author":"SM Friedewald","year":"2014","unstructured":"Friedewald SM, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014;311(24):2499\u2013507.","journal-title":"JAMA."},{"key":"20368_CR15","doi-asserted-by":"publisher","first-page":"110881","DOI":"10.1016\/j.ejrad.2023.110881","volume":"164","author":"MBI Lobbes","year":"2023","unstructured":"Lobbes MBI, et al. The performance of contrast-enhanced mammography and breast MRI in local preoperative staging of invasive lobular breast cancer. Eur J Radiol. 2023;164:110881.","journal-title":"Eur J Radiol."},{"issue":"2","key":"20368_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1097\/RCT.0000000000001663","volume":"49","author":"M Johansson Lipinski","year":"2025","unstructured":"Johansson Lipinski M, et al. Contrast-enhanced digital mammography for the diagnosis and determination of extent of disease in invasive lobular carcinoma: our experience and literature review. J Comput Assist Tomogr. 2025;49(2):258\u201364.","journal-title":"J Comput Assist Tomogr."},{"issue":"7","key":"20368_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jcu.20052","volume":"32","author":"VL Selinko","year":"2004","unstructured":"Selinko VL, Middleton LP, Dempsey PJ. Role of sonography in diagnosing and staging invasive lobular carcinoma. J Clin Ultrasound. 2004;32(7):323\u201332.","journal-title":"J Clin Ultrasound."},{"issue":"4","key":"20368_CR18","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.1148\/rg.210058","volume":"42","author":"P Manning","year":"2022","unstructured":"Manning P, et al. Invasive lobular carcinoma: a multimodality imaging primer. Radiographics. 2022;42(4):E115\u20136.","journal-title":"Radiographics."},{"issue":"1","key":"20368_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/ejso.2002.1391","volume":"29","author":"PJ Kneeshaw","year":"2003","unstructured":"Kneeshaw PJ, et al. Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer. Eur J Surg Oncol. 2003;29(1):32\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"2","key":"20368_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2214\/ajr.176.2.1760399","volume":"176","author":"SP Weinstein","year":"2001","unstructured":"Weinstein SP, et al. MR imaging of the breast in patients with invasive lobular carcinoma. AJR Am J Roentgenol. 2001;176(2):399\u2013406.","journal-title":"AJR Am J Roentgenol."},{"issue":"1","key":"20368_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-007-9528-5","volume":"107","author":"RM Mann","year":"2008","unstructured":"Mann RM, et al. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: a review of existing literature. Breast Cancer Res Treat. 2008;107(1):1\u201314.","journal-title":"Breast Cancer Res Treat."},{"key":"20368_CR22","doi-asserted-by":"crossref","unstructured":"Expert Panel on Breast, I, et al. ACR Appropriateness Criteria\u00ae imaging after breast surgery. J Am Coll Radiol. 2022;19(11S):S341-56.","DOI":"10.1016\/j.jacr.2022.09.003"},{"key":"20368_CR23","unstructured":"Expert Panel on Breast, I, et al. ACR Appropriateness Criteria\u00ae Imaging of Invasive Breast Cancer. J Am Coll Radiol. 2024;21(6S):S168-202."},{"key":"20368_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2021.11.017","volume":"61","author":"DJ O'Connor","year":"2022","unstructured":"O\u2019Connor DJ, et al. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery: a systematic review and meta-analysis. Breast. 2022;61:1\u201310.","journal-title":"Breast."},{"issue":"2","key":"20368_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cell.2015.09.033","volume":"163","author":"G Ciriello","year":"2015","unstructured":"Ciriello G, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163(2):506\u201319.","journal-title":"Cell."},{"issue":"2","key":"20368_CR26","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1245\/s10434-021-10834-0","volume":"29","author":"A Mamtani","year":"2022","unstructured":"Mamtani A, Morrow M. ASO Author Reflections: Heroic mastectomy for chemoresistant disease: a complex decision. Ann Surg Oncol. 2022;29(2):1049\u201350.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20368_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10549-012-2233-z","volume":"136","author":"EH Lips","year":"2012","unstructured":"Lips EH, et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012;136(1):35\u201343.","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"20368_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.annonc.2024.10.018","volume":"36","author":"LA Huppert","year":"2025","unstructured":"Huppert LA, et al. Pathologic complete response (pCR) rates for patients with HR+\/HER2\u2212 high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial. Ann Oncol. 2025;36(2):172\u201384.","journal-title":"Ann Oncol."},{"issue":"11","key":"20368_CR29","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.3390\/curroncol29110647","volume":"29","author":"HF Sinner","year":"2022","unstructured":"Sinner HF, et al. Surgical management of the axilla in invasive lobular carcinoma in the Z1071 era: a propensity-score matched analysis of the National Cancer Database. Curr Oncol. 2022;29(11):8197\u2013206.","journal-title":"Curr Oncol."},{"issue":"2","key":"20368_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10549-012-2002-z","volume":"133","author":"M Iorfida","year":"2012","unstructured":"Iorfida M, et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat. 2012;133(2):713\u201323.","journal-title":"Breast Cancer Res Treat."},{"issue":"9","key":"20368_CR31","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1245\/s10434-017-5898-z","volume":"24","author":"OA Petruolo","year":"2017","unstructured":"Petruolo OA, et al. Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy. Ann Surg Oncol. 2017;24(9):2556\u201362.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"20368_CR32","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1245\/s10434-025-17862-0","volume":"32","author":"RA Mukhtar","year":"2025","unstructured":"Mukhtar RA, et al. Impact of neoadjuvant chemotherapy on surgical outcomes and conversion to node-negativity in invasive lobular breast cancer: analysis of molecularly high-risk tumors by histologic subtype on the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(11):8243\u201353.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20368_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41523-025-00720-3","volume":"11","author":"RA Mukhtar","year":"2025","unstructured":"Mukhtar RA, et al. A pooled analysis evaluating prognostic significance of residual cancer burden in invasive lobular breast cancer. NPJ Breast Cancer. 2025;11(1):14.","journal-title":"NPJ Breast Cancer."},{"issue":"3","key":"20368_CR34","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1001\/jamaoncol.2023.6038","volume":"10","author":"CX Ma","year":"2024","unstructured":"Ma CX, et al. Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich\/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: a phase 3 randomized clinical trial. JAMA Oncol. 2024;10(3):362\u201371.","journal-title":"JAMA Oncol."},{"issue":"22","key":"20368_CR35","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","volume":"23","author":"IE Smith","year":"2005","unstructured":"Smith IE, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108\u201316.","journal-title":"J Clin Oncol."},{"issue":"Suppl 1","key":"20368_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10549-007-9701-x","volume":"105","author":"MJ Ellis","year":"2007","unstructured":"Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat. 2007;105(Suppl 1):33\u201343.","journal-title":"Breast Cancer Res Treat."},{"issue":"17","key":"20368_CR37","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"MJ Ellis","year":"2011","unstructured":"Ellis MJ, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype\u2013ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342\u20139.","journal-title":"J Clin Oncol."},{"issue":"10","key":"20368_CR38","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/cncr.21872","volume":"106","author":"L Cataliotti","year":"2006","unstructured":"Cataliotti L, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative \u201cArimidex\u201d Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095\u2013103.","journal-title":"Cancer."},{"issue":"4","key":"20368_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(11)70373-4","volume":"13","author":"N Masuda","year":"2012","unstructured":"Masuda N, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345\u201352.","journal-title":"Lancet Oncol."},{"key":"20368_CR40","doi-asserted-by":"crossref","unstructured":"Friedman-Eldar, O, et al. Axillary response to neoadjuvant therapy in node-positive, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: predictors and oncologic outcomes. Ann Surg Oncol. 2022.","DOI":"10.1245\/s10434-022-11473-9"},{"issue":"11","key":"20368_CR41","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.1245\/s10434-021-09715-3","volume":"28","author":"RA Mukhtar","year":"2021","unstructured":"Mukhtar RA, et al. Changes in management strategy and impact of neoadjuvant therapy on extent of surgery in invasive lobular carcinoma of the breast: analysis of the National Cancer Database (NCDB). Ann Surg Oncol. 2021;28(11):5867\u201377.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"20368_CR42","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/bjc.2013.151","volume":"108","author":"G Allevi","year":"2013","unstructured":"Allevi G, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and\/or progesterone receptor-positive breast cancer. Br J Cancer. 2013;108(8):1587\u201392.","journal-title":"Br J Cancer."},{"issue":"11","key":"20368_CR43","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.annonc.2025.07.008","volume":"36","author":"K Van Baelen","year":"2025","unstructured":"Van Baelen K, et al. Clinical challenges and proposed solutions for patients with invasive lobular breast cancer. Ann Oncol. 2025;36(11):1285\u201398.","journal-title":"Ann Oncol."},{"issue":"2","key":"20368_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.seminoncol.2019.03.002","volume":"46","author":"M Thomas","year":"2019","unstructured":"Thomas M, et al. Invasive lobular breast cancer: a review of pathogenesis, diagnosis, management, and future directions of early stage disease. Semin Oncol. 2019;46(2):121\u201332.","journal-title":"Semin Oncol."},{"key":"20368_CR45","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.clinimag.2019.05.006","volume":"57","author":"M Bahl","year":"2019","unstructured":"Bahl M, et al. MRI predictors of tumor-positive margins after breast-conserving surgery. Clin Imaging. 2019;57:45\u20139.","journal-title":"Clin Imaging."},{"issue":"6","key":"20368_CR46","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1097\/00000658-200006000-00012","volume":"231","author":"MM Moore","year":"2000","unstructured":"Moore MM, et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg. 2000;231(6):877\u201382.","journal-title":"Ann Surg."},{"key":"20368_CR47","doi-asserted-by":"crossref","unstructured":"Silverstein MJ, et al. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer. 1994;73(6):1673-7.","DOI":"10.1002\/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO;2-B"},{"issue":"12","key":"20368_CR48","doi-asserted-by":"publisher","first-page":"7383","DOI":"10.1245\/s10434-021-09865-4","volume":"28","author":"MEM van der Noordaa","year":"2021","unstructured":"van der Noordaa MEM, et al. Breast-conserving therapy in patients with cT3 breast cancer with good response to neoadjuvant systemic therapy results in excellent local control: a comprehensive cancer center experience. Ann Surg Oncol. 2021;28(12):7383\u201394.","journal-title":"Ann Surg Oncol."},{"key":"20368_CR49","doi-asserted-by":"crossref","unstructured":"Yeatman TJ, et al. Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg. 1995;222(4):549-59; discussion 559-61.","DOI":"10.1097\/00000658-199510000-00012"},{"key":"20368_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1200\/EDBK_100002","volume":"35","author":"GW Sledge","year":"2016","unstructured":"Sledge GW, Chagpar A, Perou C. Collective wisdom: lobular carcinoma of the breast. Am Soc Clin Oncol Educ Book. 2016;35:18\u201321.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"1","key":"20368_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjsurg.2020.05.038","volume":"221","author":"MK Abel","year":"2021","unstructured":"Abel MK, et al. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater. Am J Surg. 2021;221(1):32\u20136.","journal-title":"Am J Surg."},{"issue":"11","key":"20368_CR52","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1245\/s10434-018-6682-4","volume":"25","author":"RA Mukhtar","year":"2018","unstructured":"Mukhtar RA, et al. Breast conservation and negative margins in invasive lobular carcinoma: the impact of oncoplastic surgery and shave margins in 358 patients. Ann Surg Oncol. 2018;25(11):3165\u201370.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"20368_CR53","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1245\/s10434-025-17329-2","volume":"32","author":"KM Switalla","year":"2025","unstructured":"Switalla KM, et al. Positive margin rates after breast-conserving surgery by histologic subtype: a systematic review and meta-analysis evaluating the impact of oncoplastic surgery. Ann Surg Oncol. 2025;32(7):4899\u2013909.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"20368_CR54","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1245\/s10434-024-15326-5","volume":"31","author":"I Falade","year":"2024","unstructured":"Falade I, et al. Oncologic safety of immediate oncoplastic surgery compared with standard breast-conserving surgery for patients with invasive lobular carcinoma. Ann Surg Oncol. 2024;31(11):7409\u201317.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20368_CR55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.amjsurg.2021.05.021","volume":"223","author":"KC Hewitt","year":"2022","unstructured":"Hewitt KC, et al. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: incidence and management strategies. Am J Surg. 2022;223(4):699\u2013704.","journal-title":"Am J Surg."},{"issue":"5","key":"20368_CR56","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1245\/s10434-020-09042-z","volume":"28","author":"JD Son","year":"2021","unstructured":"Son JD, et al. Oncological outcomes of total skin-sparing mastectomy for invasive lobular carcinoma of the breast: a 20-year institutional experience. Ann Surg Oncol. 2021;28(5):2555\u201360.","journal-title":"Ann Surg Oncol."},{"issue":"12","key":"20368_CR57","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1245\/s10434-008-0153-2","volume":"15","author":"EA Mittendorf","year":"2008","unstructured":"Mittendorf EA, et al. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008;15(12):3369\u201377.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20368_CR58","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10549-020-06047-w","volume":"185","author":"K Schumacher","year":"2021","unstructured":"Schumacher K, et al. Is axillary imaging for invasive lobular carcinoma accurate in determining clinical node staging? Breast Cancer Res Treat. 2021;185(3):567\u201372.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"20368_CR59","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.clbc.2016.03.007","volume":"16","author":"W Truin","year":"2016","unstructured":"Truin W, et al. Sentinel lymph node biopsy and isolated tumor cells in invasive lobular versus ductal breast cancer. Clin Breast Cancer. 2016;16(4):e75-82.","journal-title":"Clin Breast Cancer."},{"issue":"4","key":"20368_CR60","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.amjsurg.2007.06.017","volume":"194","author":"JC Boughey","year":"2007","unstructured":"Boughey JC, et al. Utility of ultrasound and fine-needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. Am J Surg. 2007;194(4):450\u20135.","journal-title":"Am J Surg."},{"issue":"1","key":"20368_CR61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2214\/AJR.21.26135","volume":"218","author":"HL Chung","year":"2022","unstructured":"Chung HL, et al. Axillary nodal metastases in invasive lobular carcinoma versus invasive ductal carcinoma: comparison of node detection and morphology by ultrasound. AJR Am J Roentgenol. 2022;218(1):33\u201341.","journal-title":"AJR Am J Roentgenol."},{"issue":"7","key":"20368_CR62","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.ejso.2014.03.026","volume":"40","author":"A Topps","year":"2014","unstructured":"Topps A, et al. The sensitivity of pre-operative axillary staging in breast cancer: comparison of invasive lobular and ductal carcinoma. Eur J Surg Oncol. 2014;40(7):813\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"11","key":"20368_CR63","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1093\/jnci\/djac157","volume":"114","author":"S Oesterreich","year":"2022","unstructured":"Oesterreich S, et al. Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast cancer. J Natl Cancer Inst. 2022;114(11):1511\u201322.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"20368_CR64","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10549-020-05842-9","volume":"184","author":"W Gao","year":"2020","unstructured":"Gao W, et al. Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis. Breast Cancer Res Treat. 2020;184(1):193\u2013202.","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"20368_CR65","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10549-011-1565-4","volume":"128","author":"T Vandorpe","year":"2011","unstructured":"Vandorpe T, et al. Lobular and non-lobular breast cancers differ regarding axillary lymph node metastasis: a cross-sectional study on 4,292 consecutive patients. Breast Cancer Res Treat. 2011;128(2):429\u201335.","journal-title":"Breast Cancer Res Treat."},{"issue":"10","key":"20368_CR66","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1245\/s10434-015-4756-0","volume":"22","author":"A Roberts","year":"2015","unstructured":"Roberts A, et al. The importance of applying ACOSOG Z0011 criteria in the axillary management of invasive lobular carcinoma: a multi-institutional cohort study. Ann Surg Oncol. 2015;22(10):3397\u2013401.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"20368_CR67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12957-024-03375-9","volume":"22","author":"C Cipolla","year":"2024","unstructured":"Cipolla C, et al. Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma. World J Surg Oncol. 2024;22(1):100.","journal-title":"World J Surg Oncol."},{"issue":"11","key":"20368_CR68","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9(11):1557\u201364.","journal-title":"JAMA Oncol."},{"issue":"11","key":"20368_CR69","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","volume":"392","author":"T Reimer","year":"2025","unstructured":"Reimer T, et al. Axillary surgery in breast cancer - primary results of the INSEMA trial. N Engl J Med. 2025;392(11):1051\u201364.","journal-title":"N Engl J Med."},{"issue":"1","key":"20368_CR70","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1097\/AS9.0000000000000405","volume":"5","author":"C Tinterri","year":"2024","unstructured":"Tinterri C, Canavese G, Gentile D. To dissect or not to dissect? The surgeon\u2019s perspective on the prediction of greater than or equal to 4 axillary lymph node metastasis in early-stage breast cancer: a comparative analysis of the per-protocol population of the SINODAR-ONE clinical trial. Ann Surg Open. 2024;5(1):e405.","journal-title":"Ann Surg Open."},{"issue":"14","key":"20368_CR71","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1200\/JCO-25-00099","volume":"43","author":"KU Park","year":"2025","unstructured":"Park KU, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2025;43(14):1720\u201341.","journal-title":"J Clin Oncol."},{"issue":"13","key":"20368_CR72","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390(13):1163\u201375.","journal-title":"N Engl J Med."},{"issue":"10","key":"20368_CR73","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA."},{"key":"20368_CR74","doi-asserted-by":"crossref","unstructured":"Wang J, et al. Outcomes of sentinel lymph node dissection alone vs. axillary lymph node dissection in early stage invasive lobular carcinoma: a retrospective study of the surveillance, epidemiology and end results (SEER) database. PLoS One. 2014. 9(2):e89778.","DOI":"10.1371\/journal.pone.0089778"},{"issue":"11","key":"20368_CR75","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, et al. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(11):4515\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"20368_CR76","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1245\/s10434-019-07564-9","volume":"26","author":"MJ Thornton","year":"2019","unstructured":"Thornton MJ, et al. Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma. Ann Surg Oncol. 2019;26(10):3166\u201377.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"20368_CR77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181\u20135.","journal-title":"Histopathology."},{"issue":"4","key":"20368_CR78","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R","volume":"61","author":"H Aberle","year":"1996","unstructured":"Aberle H, Schwartz H, Kemler R. Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem. 1996;61(4):514\u201323.","journal-title":"J Cell Biochem."},{"issue":"4","key":"20368_CR79","first-page":"987","volume":"142","author":"C Gamallo","year":"1993","unstructured":"Gamallo C, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol. 1993;142(4):987\u201393.","journal-title":"Am J Pathol."},{"issue":"24","key":"20368_CR80","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1002\/j.1460-2075.1995.tb00301.x","volume":"14","author":"G Berx","year":"1995","unstructured":"Berx G, et al. E-cadherin is a tumour\/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14(24):6107\u201315.","journal-title":"EMBO J."},{"issue":"9","key":"20368_CR81","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2024.10852","volume":"332","author":"CE Ryan","year":"2024","unstructured":"Ryan CE, et al. Germline CDH1 variants and lifetime cancer risk. JAMA. 2024;332(9):722\u20139.","journal-title":"JAMA."},{"issue":"8","key":"20368_CR82","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1016\/S1470-2045(20)30219-9","volume":"21","author":"VR Blair","year":"2020","unstructured":"Blair VR, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386\u201397.","journal-title":"Lancet Oncol."},{"issue":"1","key":"20368_CR83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41523-023-00585-4","volume":"9","author":"LA Gamble","year":"2023","unstructured":"Gamble LA, et al. Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics. NPJ Breast Cancer. 2023;9(1):77.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"20368_CR84","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1001\/jamasurg.2021.5118","volume":"157","author":"LA Gamble","year":"2022","unstructured":"Gamble LA, et al. Association between hereditary lobular breast cancer due to CDH1 variants and gastric cancer risk. JAMA Surg. 2022;157(1):18\u201322.","journal-title":"JAMA Surg."},{"issue":"8","key":"20368_CR85","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1245\/s10434-025-17366-x","volume":"32","author":"VD Huynh","year":"2025","unstructured":"Huynh VD, et al. Characterization of the germline pathogenic mutational landscape and oncologic outcomes among 877 patients with invasive lobular carcinoma. Ann Surg Oncol. 2025;32(8):5477\u201388.","journal-title":"Ann Surg Oncol."},{"issue":"23","key":"20368_CR86","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA."},{"issue":"23","key":"20368_CR87","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","volume":"34","author":"MK Schmidt","year":"2016","unstructured":"Schmidt MK, et al. Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers. J Clin Oncol. 2016;34(23):2750\u201360.","journal-title":"J Clin Oncol."},{"issue":"5","key":"20368_CR88","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351.","journal-title":"N Engl J Med."},{"key":"20368_CR89","doi-asserted-by":"publisher","first-page":"117822342110702","DOI":"10.1177\/11782234211070217","volume":"16","author":"MC Braasch","year":"2022","unstructured":"Braasch MC, et al. Prognostic significance of lobular carcinoma in-situ (LCIS) diagnosed alongside invasive breast cancer. Breast Cancer (Auckl). 2022;16:11782234211070216.","journal-title":"Breast Cancer (Auckl)."},{"issue":"1","key":"20368_CR90","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/tbj.12062","volume":"19","author":"SL Blair","year":"2013","unstructured":"Blair SL, et al. Breast surgeon\u2019s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 2013;19(1):116\u20138.","journal-title":"Breast J."},{"key":"20368_CR91","unstructured":"Beck AC. Breast cancer breast conservation surgery margins 2024. Accessed December 22, 2025. https:\/\/www.breastsurgeons.org\/docs\/statements\/asbrs-rg-margins.pdf."},{"issue":"10","key":"20368_CR92","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.1245\/s10434-023-13899-1","volume":"30","author":"AC Beck","year":"2023","unstructured":"Beck AC, et al. Does non-classic lobular carcinoma in situ at the lumpectomy margin increase local recurrence? Ann Surg Oncol. 2023;30(10):6061\u20139.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"20368_CR93","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1245\/s10434-019-07796-9","volume":"26","author":"ME Miller","year":"2019","unstructured":"Miller ME, et al. Risk of contralateral breast cancer in women with ductal carcinoma in situ associated with synchronous ipsilateral lobular carcinoma in situ. Ann Surg Oncol. 2019;26(13):4317\u201325.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"20368_CR94","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart M, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22(4):476\u201388.","journal-title":"Lancet Oncol."},{"issue":"25","key":"20368_CR95","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med."},{"issue":"2","key":"20368_CR96","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med."},{"issue":"4","key":"20368_CR97","doi-asserted-by":"publisher","first-page":"478","DOI":"10.5858\/arpa.2020-0837-OA","volume":"146","author":"HE Gulbahce","year":"2022","unstructured":"Gulbahce HE, et al. The 21-gene recurrence score in special histologic subtypes of breast cancer. Arch Pathol Lab Med. 2022;146(4):478\u201384.","journal-title":"Arch Pathol Lab Med."},{"key":"20368_CR98","doi-asserted-by":"publisher","first-page":"115222","DOI":"10.1016\/j.ejca.2025.115222","volume":"217","author":"O Metzger Filho","year":"2025","unstructured":"Metzger Filho O, et al. Survival outcomes for patients with invasive lobular cancer by MammaPrint: results from the MINDACT phase III trial. Eur J Cancer. 2025;217:115222.","journal-title":"Eur J Cancer."},{"key":"20368_CR99","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41523-019-0113-y","volume":"5","author":"AE McCart Reed","year":"2019","unstructured":"McCart Reed AE, et al. LobSig is a multigene predictor of outcome in invasive lobular carcinoma. NPJ Breast Cancer. 2019;5:18.","journal-title":"NPJ Breast Cancer."},{"issue":"1","key":"20368_CR100","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-024-00627-5","volume":"10","author":"K Van Baelen","year":"2024","unstructured":"Van Baelen K, et al. Reporting on invasive lobular breast cancer in clinical trials: a systematic review. NPJ Breast Cancer. 2024;10(1):23.","journal-title":"NPJ Breast Cancer."},{"issue":"18","key":"20368_CR101","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2007.14.9336","volume":"26","author":"BC Pestalozzi","year":"2008","unstructured":"Pestalozzi BC, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26(18):3006\u201314.","journal-title":"J Clin Oncol."},{"issue":"6","key":"20368_CR102","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.breast.2013.06.001","volume":"22","author":"T Korhonen","year":"2013","unstructured":"Korhonen T, et al. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. Breast. 2013;22(6):1119\u201324.","journal-title":"Breast."},{"issue":"6","key":"20368_CR103","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1055\/s-0043-109374","volume":"77","author":"A Mathew","year":"2017","unstructured":"Mathew A, et al. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe Frauenheilkd. 2017;77(6):660\u20136.","journal-title":"Geburtshilfe Frauenheilkd."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20368-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20368-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:05:48Z","timestamp":1790870748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20368-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":103,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20368"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20368-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"1 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Meghan Flanagan: intuitive\u2014financial support for study activities to the institution, travel for training; Perimeter\u2014financial support for study activities to the institution; Rita Mukhtar: research funding from GE Healthcare.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}